LON:GSK GSK (GSK) Share Price, News & Analysis GBX 1,470 -18.50 (-1.24%) As of 06:11 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesSustainabilityBuy This Stock About GSK Stock (LON:GSK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GSK alerts:Sign Up Key Stats Today's Range 1,468▼ 1,48350-Day Range 1,354▼ 1,558.5052-Week Range 1,282.50▼ 1,823.50Volume26.80 million shsAverage Volume18.49 million shsMarket Capitalization£59.65 billionP/E Ratio23.75Dividend Yield4.08%Price TargetGBX 1,805.83Consensus RatingModerate Buy Company OverviewGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.Read More… Remove Ads GSK Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreGSK MarketRank™: GSK scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingGSK has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageGSK has only been the subject of 1 research reports in the past 90 days.Read more about GSK's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 23.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.59.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 23.88, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.62.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.24. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 4.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GSK. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 4.25%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 96.92%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about GSK's dividend. Sustainability and ESG4.4 / 5Environmental Score-1.56 Short InterestThere is no current short interest data available for GSK. News and Social Media2.4 / 5News Sentiment0.41 News SentimentGSK has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for GSK this week, compared to 5 articles on an average week.Search Interest36 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GSK to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GSK insiders have sold 28,204.48% more of their company's stock than they have bought. Specifically, they have bought £8,120.40 in company stock and sold £2,298,436.71 in company stock.Percentage Held by InsidersOnly 1.61% of the stock of GSK is held by insiders.Percentage Held by Institutions45.33% of the stock of GSK is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GSK's insider trading history. Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesWendy Becker Acquires 536 Shares of GSK plc (LON:GSK) StockMarch 22, 2025 | insidertrades.comGSK's (GSK) "Underweight" Rating Reiterated at JPMorgan Chase & Co.March 30 at 1:37 AM | americanbankingnews.comNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.March 31, 2025 | Brownstone Research (Ad)GSK Wants UK to Open Up Health Records to Boost Drug DevelopmentMarch 28 at 2:43 AM | bloomberg.comGSK accuses Pfizer of delaying Covid vaccine result until after US electionMarch 27, 2025 | yahoo.comU.S. Prosecutors Probe Tip About Timing of Pfizer VaccineMarch 26, 2025 | msn.comGSK Studying If Blockbuster Shingles Shot Reduces Dementia RiskMarch 24, 2025 | bloomberg.comIs magic suddenly happening to the dirt cheap GSK share price?March 23, 2025 | msn.comSee More Headlines GSK Stock Analysis - Frequently Asked Questions How have GSK shares performed this year? GSK's stock was trading at GBX 1,346.50 on January 1st, 2025. Since then, GSK stock has increased by 9.8% and is now trading at GBX 1,478. View the best growth stocks for 2025 here. How were GSK's earnings last quarter? GSK plc (LON:GSK) issued its quarterly earnings results on Wednesday, February, 5th. The company reported $23.20 earnings per share for the quarter. GSK had a trailing twelve-month return on equity of 18.08% and a net margin of 8.02%. How do I buy shares of GSK? Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some other companies that GSK investors own include AstraZeneca (AZN), Vodafone Group Public (VOD), Lloyds Banking Group (LLOY), Secure Trust Bank (STB), Barclays (BARC), Meta Platforms (META) and Intel (INTC). Company Calendar Record date for 1/9 Dividend11/14/2024Ex-Dividend for 1/9 Dividend11/14/2024Dividend Payable1/09/2025Last Earnings2/05/2025Today3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:GSK CIKN/A Webwww.gsk.com Phone+44-20-80475000FaxN/AEmployees70,212Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 1,805.83 High Stock Price TargetGBX 2,100 Low Stock Price TargetGBX 1,600 Potential Upside/Downside+22.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 61.91 Trailing P/E Ratio23.88 Forward P/E Ratio8.40 P/E Growth1.24Net Income£2.50 billion Net Margins8.02% Pretax MarginN/A Return on Equity18.08% Return on Assets9.56% Debt Debt-to-Equity Ratio114.64 Current Ratio0.81 Quick Ratio0.73 Sales & Book Value Annual Sales£31.14 billion Price / Sales1.93 Cash FlowGBX 181.45 per share Price / Cash Flow8.15 Book ValueGBX 329.73 per share Price / Book4.48Miscellaneous Outstanding Shares4,057,829,779Free FloatN/AMarket Cap£59.97 billion OptionableNot Optionable Beta0.31 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (LON:GSK) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. Share GSK With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.